HAVRIX is indicated for active immunization > 12 months of age against disease caused by hepatitis A virus (HAV).
- HAVRIX is administered as a 2-dose series with the initial dose followed by a booster dose 6 to 12 months later
Important Safety Information
In clinical trials, the most common solicited adverse events were injection-site soreness and headache. Greater incidences of general adverse events were observed in subjects who received HAVRIX at the same time as Hib conjugate and DTaP vaccines. As with any vaccine, rare adverse events may occur. (See Adverse Reactions section of the Prescribing Information for HAVRIX for potential side effects.) HAVRIX is contraindicated in people with hypersensitivity to any component of the vaccine, including neomycin.
Taken from www.havrix.com